ArticleJournal of the National Cancer Institute2014
Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities.
Article in Journal of the National Cancer Institute, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03935282 (Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors), which is not on this map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors (AH-HA)
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk Factors for Anthracycline-Induced Cardiotoxicity.Frontiers in cardiovascular medicine · 2021Pooled it
- Cancer treatment-related cardiotoxicity, molecular mechanism, challenges, and research trends.Discover oncology · 2026Review
- Risk of Cardiovascular Disease in Cancer Survivors after Systemic Treatment: A Population-Based Cohort Study.JACC. CardioOncology · 2025Article
- Understanding the Mechanisms of Chemotherapy-Related Cardiotoxicity Employing hiPSC-Derived Cardiomyocyte Models for Drug Screening and the Identification of Genetic and Epigenetic Variants.International journal of molecular sciences · 2025Review
- Oncology Provider and Patient Perspectives on a Cardiovascular Health Assessment Tool Used During Posttreatment Survivorship Care in Community Oncology (Results from WF-1804CD): Mixed Methods Observational Study.Journal of medical Internet research · 2025Observational
- Physical activity and incident cardiovascular disease in breast cancer survivors: the Pathways Study.JNCI cancer spectrum · 2025Article
- CardioAI: A Multimodal AI-based System to Support Symptom Monitoring and Risk Prediction of Cancer Treatment-Induced Cardiotoxicity.Proceedings of the SIGCHI conference on human factors in computing systems. CHI Conference · 2025Article
- Navigating the crossroads: cardiometabolic risks in cancer survivorship - a comprehensive review.Cardio-oncology (London, England) · 2024Review
- Navigating the crossroads: cardiometabolic risks in cancer survivorship - a comprehensive review.Cardio-oncology (London, England) · 2024Review
- Cardiovascular health assessment in routine cancer follow-up in community settings: survivor risk awareness and perspectives.BMC cancer · 2024Article
- Incident Cardiovascular Disease Risk among Older Asian, Native Hawaiian and Pacific Islander Breast Cancer Survivors.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Determining the association of rurality and cardiovascular disease among prostate cancer survivors.Urologic oncology · 2023Article
- Incorporating Exercise Training into Cardio-Oncology Care: Current Evidence and Opportunities:JACC. CardioOncology · 2023Review
- Mortality and Major Adverse Cardiac Events in Patients With Breast Cancer Receiving Radiotherapy: The First Decade.Journal of the American Heart Association · 2023Article
- Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma.Biomedicines · 2023Review
- Cardiotoxicity among socioeconomically marginalized breast cancer patients.Breast cancer research and treatment · 2022Article
- The Impact of the Cancer Moonshot on Cardio-Oncology Science.JACC. CardioOncology · 2022Article
- Spectrum of National Institutes of Health-Funded Research in Cardio-Oncology: A Basic, Clinical, and Observational Science Perspective.Heart failure clinics · 2022Review
- Cardiovascular Assessment Tool for Breast Cancer Survivors and Oncology Providers: Usability Study.JMIR cancer · 2021Article
- Clinical Practice and Research in Cardio-Oncology: Finding the "Rosetta Stone" for Establishing Program Excellence in Cardio-oncology.Journal of cardiovascular translational research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cardiotoxicity resulting from direct myocyte damage has been a known complication of cancer treatment for decades. More recently, the emergence of hypertension as a clinically significant side effect of several new agents has been recognized as adversely affecting cancer treatment outcomes. With cancer patients living longer, in part because of treatment advances, these adverse events have become increasingly important to address. However, little is known about the cardiovascular pathogenic mechanisms associated with cancer treatment and even less about how to optimally prevent and manage short- and long-term cardiovascular complications, leading to improved patient safety and clinical outcomes. To identify research priorities, allocate resources, and establish infrastructure required to address cardiotoxicity associated with cancer treatment, the National Cancer Institute (NCI) and National Heart, Lung and Blood Institute (NHLBI) sponsored a two-day workshop, "Cancer treatment-related cardiotoxicity: Understanding the current state of knowledge and future research priorities," in March 2013 in Bethesda, MD. Participants included leading oncology and cardiology researchers and health professionals, patient advocates and industry representatives, with expertise ranging from basic to clinical science. Attendees were charged with identifying research opportunities to advance the understanding of cancer treatment-related cardiotoxicity across basic and clinical science. This commentary highlights the key discussion points and overarching recommendations from that workshop.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.